SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
SC_12-0104_sm_supplFigure1.pdf289KFigure S1. Mock transduced Krt-15 mice do not express GFP in peripheral blood. Representative FACS profiles of PB cells of mock transduced control mice at day 86 after IF-injection. (20,000 living PB cells analyzed)
SC_12-0104_sm_supplFigure2.pdf349KFigure S2. Multilineage contribution of marked cells to lonG−term hematopoiesis. Myeloid (CD11b+/Ly6G−, CD11b+/Ly6G+, Ter119+) and lymphoid (CD3+/CD4+, CD3+/CD8+, CD19+) GFP+ cells detected in PB of marked mice at different time points after IF injection of lentiviral vector. Similar activity of GFP marked myeloid and lymphoid cells were obtained. (PB= peripheral blood, d= day, Mo= months, IF= intrafemoral, y-axis is logarithmically scaled)
SC_12-0104_sm_supplFigure3.pdf176KFigure S3. Myeloid (CD11b+/Ly6G−, CD11b+/Ly6G+, Ter119+) and lymphoid (CD3+/CD4+, CD3+/CD8+, CD19+) GFP+ cells contribute to hematopoiesis at different time points after intravenous injection of lentiviral vector. (PB= peripheral blood, d= day, Mo= months, IV= intravenous, y-axis is logarithmically scaled)
SC_12-0104_sm_supplFigure4.pdf275KFigure S4. Reduced numbers of CD11b+/Ly6G+ granulocytes in peripheral blood of Krt-15 mice treated with 5-Fluorouracil. Representative FACS profiles of PB cells of 5-FU untreated control mice (A) as compared to 5-FU treated mice at day 7 after injection of 5-FU (B). Reduced numbers of CD11b+/Ly6G+ granulocytes were obtained in PB of 5-FU injected mice. (20,000 living PB cells analyzed)
SC_12-0104_sm_supplFigure5.pdf514KFigure S5. Myeloid and lymphoid marked cells contribute to lonG−term hematopoiesis in 5-FU pretreated animals. Myeloid (CD11b+/Ly6G−, CD11b+/Ly6G+, Ter119+) or lymphoid (CD3+/CD4+, CD3+/CD8+, CD19+) blood cells were detected at different time points after intrafemoral or intravenous injection of lentiviral vector in animals treated with 5-FU prior to marking. Mice were injected intravenously with 150mg/kg of 5-FU at day 4 prior to LV-marking. (PB= peripheral blood, d= day, Mo= months, IF= intrafemoral, IV= intravenous, y-axis is logarithmically scaled)

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.